Panbela Therapeutics, Inc. (PBLA)

0.4090 -0.0012 (-0.29%) 收市：03:32PM EDT

Panbela Therapeutics, Inc.

712 Vista Boulevard
Suite 305
Waconia, MN 55387
United States
952 479 1196
https://www.panbela.com

版塊: Healthcare
行業: Biotechnology
全職員工: 7

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.	CEO, President & Director	527k	無	1968
Ms. Susan Horvath	VP of Finance, CFO, Secretary & Treasurer	452.39k	無	1959
Ms. Tammy Groene	Vice President of Operations	無	無	無
Dr. Elizabeth Bruckheimer Ph.D.	VP & Chief Scientific Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

公司管治

截至 無 止，Panbela Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。